Cointime update: Gilead reported that twice-yearly lenacapavir achieved 85.6% one-year persistence for HIV pre-exposure prophylaxis, nearly double that of daily oral F/TDF. No HIV infections occurred in the lenacapavir group during the 52-week study period, compared with one infection in the daily oral F/TDF group. Serious adverse events were uncommon and unrelated to treatment, with no discontinuations due to adverse events in the lenacapavir arm.
Gilead: Twice-Yearly Lenacapavir Shows Near Double the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
24m ago
Binance Hot Wallet Attacker Moves 78,415 ETH Worth $142M
34m ago
Binance Plans to Enter Five Asian Markets Next Year, Focus on South and Southeast Asia
51m ago
Binance Wallet Anthropic IPO Subscription Hits $338M USDC
54m ago
Anthropic Perpetual Futures Imply $1.7T Valuation
1h ago
Huobi HTX Lists TMO/USDT Perpetual Contract With Up to 20x Leverage
2h ago
Binance to Launch USDT Perpetual Contracts for Six TradFi Assets